Camurus receives improved ESG risk rating by Sustainalytics
Camurus works to sustainably contribute to improving health for patients with severe and chronic diseases by developing innovative and potentially life-changing medicines for the benefit of patients, caregivers, and society at large.
The company conducts a continuous and strategic sustainability work. An indication that the company is on the right track is the recently updated ESG ranking from Sustainalytics, in which Camurus improves the sustainability risk level to a medium risk ranking better than the average within the pharmaceutical industry subcategory.
“In recent years, we have substantially strengthened our systematic sustainability work at Camurus. This has resulted in an improved risk level from Sustainalytics, but also in a recently improved ESG-ranking by Nordea where Camurus received AAA, the best level,” says Fredrik Tiberg, President & CEO at Camurus. “Camurus has a sustainability product contributing to great social benefit, but naturally, we must have control of the sustainability risks and ensure our products are manufactured in an environmentally and socially responsible manner.”
“Camurus’ sustainability work is integrated into our operations, and we are on a journey towards continuous improvement. Focus going forward is to minimize our products’ environmental footprint throughout the value chain, manage sustainability risks in the supply chain in collaboration with our suppliers, and our employees’ engagement”, says Iris Rehnström, Director Sustainability at Camurus. “Also, social aspects are important, and we actively work to be an inclusive workplace where everyone thrives and has the opportunity to develop their skills and abilities, which is measured in our regular employee surveys.”
Sustainalytics' evaluation is based on a comprehensive risk analysis of environmental, social and governance risks. Environmental risks include greenhouse gas emissions, environmental management systems, use of renewable energy and management of hazardous waste. Social risks include discrimination, equality, human rights in the value chain, ethical marketing, product safety and access to medicines. Governance risks include areas such as business ethics, corruption and whistleblowing.
For Sustainalytics’ results see: https://www.sustainalytics.com/esg-rating/camurus-ab/1008297536
For more information about Camurus’ sustainability work see: https://www.camurus.com/sustainability/
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.